ABNX — Abionyx Pharma SA Share News
0.000.00%
Last trade - 00:00- €62.99m
- €51.30m
- €4.06m
Brief: Abionyx Pharma End-Sept Cash Position OF 8.8 Million Euros
Brief: Abionyx Pharma Publishes H1 Net Income Of 2.9 Million Euros
Brief: CERENIS Therapeutics Changes Its Name To ABIONYX Pharma
Brief: Bpifrance Acknowledges Technical Failure Of Cerenis ISI Project "Apotheosis"
Brief: Cerenis End-March Cash And Cash Equivalents At 9.7 Million Euros
Brief: Cerenis Therapeutics And H4Orphan Pharma Enter Into Exclusive Negotiations For Merger
Brief: Cerenis Therapeutics FY Operating Loss Widens To 7.1 Million Euros
Brief: Cerenis Therapeutics Reports Results Of The Phase I Study Of Repeated And Increasing Doses To Assess CER-209 In NASH/NAFLD
Brief: Cerenis Therapeutics Holding Appoints Richard Pasternak As CEO
Brief: Cerenis Therapeutics Reports Results of Phase II Study To Target Tumor In Patients With Esophageal Cancer
Brief: Cerenis Says Tango Phase III Study Missed Primary Endpoint
Brief: Cerenis Therapeutics Holding Confirms No New Information About CER-001 Phase III Study
Brief: Cerenis Therapeutics Q3 Cash Holding of 12.9 Million Euros
Brief: Cerenis Therapeutics Holding H1 Net Loss Widens To EUR 3.4 Million
Brief: Cerenis Therapeutics Holding H1 Cash Position Of EUR 13.5 Million
Brief: Cerenis Therapeutics Holding Completes Capital Increase Of 1.1 Million Euros
Brief: Cerenis Therapeutics Cash Position And Activity Update For H1 2018
Brief: Cerenis Therapeutics Holding Announces First Results Of Target Phase II Study
Brief: Cerenis Therapeutics And University Of North Texas To Develop New Products